Posted On: 12/29/2014 4:28:49 PM
Post# of 30066
Noticed a difference in wording with today's PR vs. what's been published by the company in the past.
Here is the full text of the accompanying material for the retrospective analysis poster from AAIC last summer:
http://alzheimersanddementiajournal.net/artic...8/fulltext
Of note: "Results: Review of the 8 years of clinical records of the N= 28 control subjects from the original study reveals interesting prognostic information gleaned from the original wet biology biomarkers. In particular, two markers to be presented show hints of prognostic utility with weak statistical significance .
From today's PR: "The results will include the dataset from the initial 72 patients showing that LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls and from the additional 68 patients in the study's extension to assess LymPro's predictive value in diagnosing early-stage AD."
Here is the full text of the accompanying material for the retrospective analysis poster from AAIC last summer:
http://alzheimersanddementiajournal.net/artic...8/fulltext
Of note: "Results: Review of the 8 years of clinical records of the N= 28 control subjects from the original study reveals interesting prognostic information gleaned from the original wet biology biomarkers. In particular, two markers to be presented show hints of prognostic utility with weak statistical significance .
From today's PR: "The results will include the dataset from the initial 72 patients showing that LymPro achieved highly statistically significant results in correctly distinguishing patients with moderate-to-severe AD from healthy controls and from the additional 68 patients in the study's extension to assess LymPro's predictive value in diagnosing early-stage AD."
(0)
(0)
